Zhou Cheng-Bei, Pan Si-Yuan, Jin Peng, Deng Jia-Wen, Xue Jin-Hui, Ma Xin-Yue, Xie Yuan-Hong, Cao Hui, Liu Qiang, Xie Wei-Fen, Zou Xiao-Ping, Sheng Jian-Qiu, Wang Bang-Mao, Wang Hong, Ren Jian-Lin, Liu Si-De, Sun Yun-Wei, Meng Xiang-Jun, Zhao Gang, Chen Jin-Xian, Cui Yun, Wang Pei-Qin, Guo Hui-Min, Yang Lang, Chen Xin, Ding Jia, Yang Xiao-Ning, Wang Xin-Ke, Qian Ai-Hua, Hou Li-Dan, Wang Zheng, Chen Ying-Xuan, Fang Jing-Yuan
Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Gastroenterology, The First Medical Center of Chinese People's Liberation Army General Hospital, The Seventh Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Gastroenterology. 2022 Jun;162(7):1933-1947.e18. doi: 10.1053/j.gastro.2022.02.015. Epub 2022 Feb 12.
BACKGROUND & AIMS: Most patients with gastric cancer (GCa) are diagnosed at an advanced stage. We aimed to investigate novel fecal signatures for clinical application in early diagnosis of GCa.
This was an observational study that included 1043 patients from 10 hospitals in China. In the discovery cohort, 16S ribosomal RNA gene analysis was performed in paired samples (tissues and feces) from patients with GCa and chronic gastritis (ChG) to determine differential abundant microbes. Their relative abundances were detected using quantitative real-time polymerase chain reaction to test them as bacterial candidates in the training cohort. Their diagnostic efficacy was validated in the validation cohort.
Significant enrichments of Streptococcus anginosus (Sa) and Streptococcus constellatus (Sc) in GCa tumor tissues (P < .05) and feces (P < .0001) were observed in patients with intraepithelial neoplasia, early and advanced GCa. Either the signature parallel test Sa∪Sc or single signature Sa/Sc demonstrated superior sensitivity (Sa: 75.6% vs 72.1%, P < .05; Sc: 84.4% vs 64.0%, P < .001; and Sa∪Sc: 91.1% vs 81.4%, P < .01) in detecting early GCa compared with advanced GCa (specificity: Sa: 84.0% vs 83.9%, Sc: 70.4% vs 82.3%, and Sa∪Sc: 64.0% vs 73.4%). Fecal signature Sa∪Sc outperformed Sa∪CEA/Sc∪CEA in the discrimination of advanced GCa (sensitivity: 81.4% vs 74.2% and 81.4% vs 72.3%, P < .01; specificity: 73.4% vs 81.0 % and 73.4% vs 81.0%). The performance of Sa∪Sc in the diagnosis of both early and advanced GCa was verified in the validation cohort.
Fecal Sa and Sc are noninvasive, accurate, and sensitive signatures for early warning in GCa. (ClinicalTrials.gov, Number: NCT04638959).
大多数胃癌(GCa)患者确诊时已处于晚期。我们旨在研究用于GCa早期诊断临床应用的新型粪便标志物。
这是一项观察性研究,纳入了来自中国10家医院的1043例患者。在发现队列中,对GCa患者和慢性胃炎(ChG)患者的配对样本(组织和粪便)进行16S核糖体RNA基因分析,以确定差异丰富的微生物。使用定量实时聚合酶链反应检测它们的相对丰度,以在训练队列中将它们作为细菌候选物进行测试。在验证队列中验证它们的诊断效能。
在伴有上皮内瘤变、早期和晚期GCa的患者中,观察到GCa肿瘤组织(P <.05)和粪便(P <.0001)中咽峡炎链球菌(Sa)和星座链球菌(Sc)显著富集。与晚期GCa相比,标志物平行检测Sa∪Sc或单一标志物Sa/Sc在检测早期GCa时表现出更高的敏感性(Sa:75.6%对72.1%,P <.05;Sc:84.4%对64.0%,P <.001;Sa∪Sc:91.1%对81.4%,P <.01)(特异性:Sa:84.0%对83.9%,Sc:70.4%对82.3%,Sa∪Sc:64.0%对73.4%)。粪便标志物Sa∪Sc在鉴别晚期GCa方面优于Sa∪CEA/Sc∪CEA(敏感性:81.4%对74.2%和81.4%对72.3%,P <.01;特异性:73.4%对81.0%和73.4%对81.0%)。在验证队列中验证了Sa∪Sc在早期和晚期GCa诊断中的性能。
粪便中的Sa和Sc是GCa早期预警的无创、准确且敏感的标志物。(ClinicalTrials.gov编号:NCT04638959)